Coagulation system and inflammatory bowel disease: Therapeutic and pathophysiologic implications;Gerinnungssystem und chronisch entzündliche darmerkrankungen: Therapeutische und pathophysiologische implikationen

Zeitschrift fur Gastroenterologie

Volumn 40, Issue 12, 2002, Pages 991-998

  Folwaczny, Christian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Crohn's disease; Heparin; Ulcerative colitis

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBROBLAST GROWTH FACTOR; LOW MOLECULAR WEIGHT HEPARIN;

BLOOD CLOTTING; CIRCULATION; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENTERITIS; HEMOSTASIS; HEPARINIZATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTESTINE WALL; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; THROMBOEMBOLISM; ULCERATIVE COLITIS;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; CLINICAL TRIALS; COLITIS, ULCERATIVE; CONTROLLED CLINICAL TRIALS; CROHN DISEASE; FACTOR XIII; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MULTICENTER STUDIES; PILOT PROJECTS; PLACEBOS; PROSPECTIVE STUDIES;

EID: 0036926156     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36158     Document Type: Review

References (79)

1. Lam A, Borda IT, Inwood MJ et al. Coagulation studies in ulcerative colitis and Crohn's disease. Gastroenterology 1975; 68: 245-251
2. Sankey EA, Dhillon AP, Anthony A et al. Early mucosal changes in Crohn's disease. Gut 1993; 34: 375-381
3. Wakefield AJ, Sawyer AM, Dhillon AP et al. Pathogenesis of Crohn's disease: Multifocal gastrointestinal infarction. Lancet 1989; 2: 1057-1062
4. Hudson M, Hutton RA, Wakefield AJ et al. Evidence for activation of coagulation in Crohn's disease. Blood Coagul Fibrinolysis 1992; 3: 773-778
5. Hudson M, Chitolie A, Hutton RA et al. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996; 38: 733-737
6. Souto JC, Martinez E, Roca M et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40: 1183-1189
7. Hudson M, Wakefield AJ, Hutton RA et al. Factor XIIIa subunit and Crohn's disease. Gut 1993; 34: 75-79
8. Edwards R, Levine JB, Green R et al. Activation of blood coagulation in Crohn's disease: Increased plasma fibrinopeptide A levels and enhanced generation of monocyte tissue factor activity. Gastroenterology 1987; 92: 329-332
9. Collins CE, Rampton DS. Review article: Platelets in inflammatory bowel disease-pathogenetic role and therapeutic implications. Aliment Pharmacol Ther 1997; 11: 237-247
10. White B, Ang YS, Mahmud N et al. Heparin and inflammatory bowel disease. Lancet 1999; 354: 1122-1123
11. Wakefield AJ, Pittilo RM, Sim R. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 1993; 39: 345-353
12. Wakefield AJ, Sim R, Akbar AN. In situ immune responses in Crohn's disease: A comparison with acute and persistent measles virus infection. J Med Virol 1997; 51: 90-100
13. Dhillon AP, Anthony A, Sim R et al. Mucosal capillary thrombi in rectal biopsies. Histopathology 1992; 21: 127-133
14. Langman MJS. Can incoagulable blood protect against inflammatory bowel disease? Gastroenterology 1995; 108: 1305-1307
15. Thompson NP, Wakefield AJ, Pounder RE. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995; 108: 1011-1015
16. Folwaczny C, Loeschke K, Schnettler D et al. Endothelial autoantibodies are a marker of disease susceptibility in inflammatory bowel disease but apparently not linked to persistent measles virus infection. Clin Immunol 2000; 95: 197-202
17. Folwaczny C, Noehl N, Endres SP et al. Antinuclear autoantibodies in patients with inflammatory bowel disease: High prevalence in first-degree relatives. Dig Dis Sci 1997; 42: 1593-1597
18. Shanahan F, Duerr RH, Rotter JI et al. Neutrophil autoantibodies in ulcerative colitis: Familial aggregation and genetic heterogeneity. Gastroenterology 1992; 103: 456-461
19. Seibold F, Slametschka D, Gregor M et al. Neutrophil autoantibodies: A genetic marker in primary sclerosing cholangitis and ulcerative colitis, Gastroenterology 1994; 107: 532-536
20. Folwaczny C, Fricke H, Spannagl M et al. Heparin zur therapie der colitis ulcerosa: Therapie eines begleitphänomens oder hinweis auf die pathophysiologie? Z Gastroenterol 1995; 33: 723-724
21. Kaufman HJ Taubin HL. Non-steroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease, Ann Intern Med 1987; 107: 513-516
22. Gaffney PR, O'Leary JI, Doyle CT. Response to heparin in patients with ulcerative colitis. Lancet 1991; 337: 238-239
23. Liebman HA, Kashani N, Sutherland D et al. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenteroloy 1998; 115: 830-834
24. Spannagl M, Dick A, Folwaczny C et al. The factor V Leiden mutation in patients with inflammatory bowel disease, Gastroenterology 1999; 117: 280
25. Helio T, Wartiovaara U, Halme L et al. Arg506Gln factor V mutation and Va134Leu Factor XIII polymorphism in finnish patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 170-174
26. Haslam N, Standen GR, Probert CS. An investigation of the association of the prothrombin G20210A gene mutation and inflammatory bowel disease, Factor II and IBD. Inflamm Bowel Dis 2001; 7: 133-135
27. Chamouard P, Grunebaum L, Wiesel MJ et al. Significance of diminished factor XIII in Crohn's disease. Am J Gastroenterol 1998; 93: 610-614
28. Seitz R, Leugner F, Katschinski M et al. Ulcerative colitis and Crohn's disease: Factor XIII, inflammation and haemostasis. Digestion 1994; 55: 361-367
29. Van Bodegraaven AA, Tuynman HA, Schoorl M et al, Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease. Scand J Gastroenterol 1995; 30: 580-585
30. Oshitani N, Kiano A, Hara J. Deficiency of blood coagulation factor XIII in Crohn's disease. Am J Gastroenterol 1995; 90: 1116-1118
31. Lorenz R, Born P, Olbert P et al. Factor XIII substitution in ulcerative colitis. Lancet 1995; 345: 449-450
32. Bregenzer N, Caesar I, Andus T et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. The factor XIII study group. Z. Gastroenterol 1999; 37: 999-1004
33. Oshitani N, Nakamura S, Matsumoto T et al. Treatment of Crohn's disease fistulas with coagulation factor XIII. Lancet 1996; 347: 119-120
34. Zahernakowa TV, Kashmenskaya NA, Maltseva IV. Hemostasis and heparin therapy in non-specific ulcerative colitis. Soviet Med (Moskva) 1984; 110-113
35. Zavgorodniy LG, Mustyats AP. The use of anticoagulants in combined therapy of non-specific ulcerative colitis. Klin Med (Moskva) 1982; 60: 74-80
36. Gaffney PR, Doyle CT, Gaffney A et al. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995; 90: 220-223
37. Evans RC, Wong VS, Morris AI et al. Treatment of corticosteroid resistant ulcerative colitis with heparin - A report of 16 cases. Aliment Pharmacol Ther 1997; 11: 1037-1040
38. Folwaczny C, Wiebecke B, Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 1999: 94: 1551-1555
39. Dupas JL, Brazier F, Yzet T et al. Treatment of active Crohn's disease with heparin. Gastroenterology 1996; 110: A900
40. Brazier F, Yzet T, Boruchowicz A et al. Treatment of ulcerative colitis with heparin. Gastroenterology 1996; 110: A872
41. Evans RC, Rhodes JM. Heparin, used i. v. and with sulphasalazine, appears to be effective in the treatment of refractory U.C., and warrants larger controlled trials. Gut 1995; 37 (suppl. 2): A49
42. Folwaczny C, Spannagl M, Wiebecke B et al. Heparin in the treatment of highly active inflammatory bowel disease (IBD). Gastroenterology 1996; 110: A908
43. Iglicki F, Dupas JL. Effect of heparin treatment on extraintestinal manifestations associated with inflammatory bowel disease. Gastroenterology 1996; 110: A872
44. Torkvist L, Thorlacius H, Sjoquist U et al. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1323-1328
45. Vrij AA, Jansen JM, Schoon EJ et al. Low molecular weight heparin treatment in steroid refractory ulcerative colitis: Clinical outcome and influence on mucosal capillary thrombi. Scand J Gastroenterol Suppl 2001; 234: 41-47
46. Dotan I, Hallak A, Arber N et al. Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: An open trial, Dig Dis Sci 2001; 46: 2239-2244
47. Ang YS, Mahmud N, White B et al, Randomized comparison of unfractioned heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1015-1022
48. Panes J, Esteve M, Cabre E et al. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology 2000; 199: 903-908
49. Folwaczny C. Heparin therapy for ulcerative colitis. Gastroenterology 2001; 120: 1307-1308
50. Korzenik JR, Robert ME, Bitton A et al. A multi-center, randomized, controlled trial of heparin for the treatment of ulcerative colitis. Gastroenterology 1999; 116: G3264
51. Gorski A, Imiela J, Nosarzewski J, Oral heparin in the treatment of rheumatoid arthritis. J Immunol 1993; 150: PA239
52. Cui HF, Jiang XL. Treatment of corticosteroid-resistant ulcerative colitis with oral low molecular weight heparin. World J Gastroenterol 1999; 5: 448-450
53. Dwarakanath AD, Yu LG, Brookes C et al. 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangraenosum complicating ulcerative colitis. Gut 1995; 37: 585-588
54. Papa A, Danese S, Gasbarrini A et al. Review article: Potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1403-1409
55. Bannon PG, Kim MJ, Dean RT et al. Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin. Thromb Haemost 1995; 73: 706-712
56. Lider O, Baharm E, Mekari Y et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 1998; 83: 752-756
57. Miller SJ, Hoggatt AM, Faulk WP. Heparin regulates ICAM-1 expression in human endothelial cells: An example of non-cytokine-mediated endothelial activation. Thromb Haemost 1998; 80: 481-487
58. Chowers Y, Lider O, Schor H et al. Disaccharides derived from heparin or heparan sulfate regulate IL-8 and IL-1 β secretion by intestinal epithelial cells. Gastroenterology 2001; 120: 449-459
59. Chang NS, Intrieri C, Mattison J et al. Synthetic polysulfated hyaluronic acid is a potent inhibitor for tumor necrosis factor production. J Leukoc Biol 1994; 55: 778-784
60. Salas A, Sans M, Soriano A et al. Heparin attenuates TNF induced inflammatory response through a CD11b dependent mechanism. Gut 2000; 47: 88-96
61. Tyrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as anticoagulant. Trands Pharmacol Sci 1995; 16: 198-204
62. Lantz M, Thysell H, Nilsson E et al. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein 1 by heparin. J Clin Invest 1991; 88: 2026-2031
63. Cahalon L, Lider O, Schor H et al. Heparin disaccharides inhibit tumor necrosis factor-alpha production by macrophages and arrest immune inflammation in rodents, Int Immunol 1997; 9: 1517-1522
64. Ramdin L, Perks B, Sheron N, Shute JK. Regulation of interleukin-8 binding and function by heparin and alpha-2 macroglobulin. Clin Exp Allergy 1998; 28: 616-624
65. Dobosz M, Mionskowska L, Dobrowolski S et al. Is nitroc oxide and heparin treatment justified in inflammatory bowel disease? An experimental study. Scand J Clin Lab Invest 1996; 56: 657-663
66. Beltran AE, Conception F, Manzanares D et al. Heparin and low molecular weight heparin decrease nitric oxide production by human polymorphnuclear cells. Arch Med Res 1999; 30: 116-119
67. Kimura H, Miura S, Shigematsu T et al. Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with actrive ulcerativve colitis and Crohn's disease. Dig Dis Sci 1997; 42: 1047-1054
68. Dandona P, Qutob T, Hamoudda W et al. Heparin inhibits reactive oxygen species generation by polymorphnuclear and mononuclear leucocytes. Thromb Res 1999; 96: 437-443
69. Riesenberg K, Schaeffler F. Katz A et al. Inhibition of superoxide production in human neutrophils by combinations of heparin and thrombolytic agents. Br Heart J 1995; 73: 14-19
70. Oshitani N, Kitano A, Okabe H et al. Location of superoxide anion generation in human colonic mucosa obtained by biopsy. Gut 1993; 34: 936-938
71. Dagli U, Balk M, Yucel D et al. The role of reactive oxygen metabolites in ulcerative colitis. Inflamm Bowel Dis 1997; 3: 198-203
72. Kaplanski G, Fabrigoule M, Boulay V et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha independent IL-8 secretion and E-selectin expession. J Immunol 1997; 158: 5435-5441
73. Zimmermann G, Mcintyre T, Prescott S et al. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. J Clin Invest 1985; 76: 2235-2246
74. Folwaczny C, Fricke H, Endres S et al. Antiinflammatory properties of unfractioned heparin in patients with highly active ulcerative colitis: A pilot study. Am J Gastroenterol 1997; 92: 911-912
75. Day R, Forbes A. Heparin, cell adhesion and pathogenesis of inflammatory bowel disease. Lancet 1999; 354: 62-65
76. Bernfield M, Kokenyesi R, Kato M et al. Biology of the syndecans: A family of transmembrane heparan sulphate proteooglycans. Annu Rev Cell Biol 1992; 8: 365-393
77. Yayon A, Klagsbrun M, Esko JD et al. Cell surface, heparin like molecules are required for binding of basic fibroblast like growth factor to its high affinity receptor. Cell 1991; 64: 841-848
78. Klagsbrun M, Baird A. A dual receptor system is required for basic fibroblast like growth factor activity. Cell 1991; 67: 229-231
79. Day R, Daszak P, Talbot I et al. Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci 1999; 44: 2508-2515